Amarin Corp Plc (AMRN)

[zmanindc]

The current stock price is a direct reflection of the inability of management to educate the financial community on the global value of Vascepa. Very frustrating to be once again be stuck in Amarin purgatory where you are in the black, smacked back to red, black again only to repeat and relive the nightmare. What makes this so frustrating as a patient, we know the value and benefits of this drug.

Amarin is months away from EU approval with a patient population size 2x the US. Even if they have to reduce the price by $15 dollars the peak potential could be $3 to $5 billion a year. The contract life of Canada is worth 500 million and you still have China, with a patient population bigger than the EU. They will still need the drug no matter their global reputation. Still, this does not consider Russia the rest of the non EU countries, South America. We should be worth at minimum $20 without the US. Yet, we trade like an OTC US provider. That is on management. Sell the company at $20 with a $20 CVR for a US win.